EUVIMEDEUVIMED entdecken
Fallbericht

Glyco-polypeptides in Treating of Various Types of Late-Stage Refractory Solid Carcinoma in Humans-A Double-Blind Study-Case Report of 126 Patients: Complete Study Report of Phase II Clinical Trial

Journal of Oncology Research and Therapy · 2021

DOI: 10.29011/2574-710x.010116 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Oncology Research and Therapy, 2021.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glyco-polypeptides (Comosain) induced leucocyte binding ability to tumor surface antigens, such as interleukin 2, 6, 8, and TNFs, is known as an immuno-target therapy. Using the different concentration of Bromelain proteinases.

Zitieren

APA

(2021). Glyco-polypeptides in Treating of Various Types of Late-Stage Refractory Solid Carcinoma in Humans-A Double-Blind Study-Case Report of 126 Patients: Complete Study Report of Phase II Clinical Trial. Journal of Oncology Research and Therapy. https://doi.org/10.29011/2574-710x.010116

Vancouver

Glyco-polypeptides in Treating of Various Types of Late-Stage Refractory Solid Carcinoma in Humans-A Double-Blind Study-Case Report of 126 Patients: Complete Study Report of Phase II Clinical Trial. Journal of Oncology Research and Therapy. 2021. doi:10.29011/2574-710x.010116

BibTeX
@article{euvimed2021,
  title = {Glyco-polypeptides in Treating of Various Types of Late-Stage Refractory Solid Carcinoma in Humans-A Double-Blind Study-Case Report of 126 Patients: Complete Study Report of Phase II Clinical Trial},
  journal = {Journal of Oncology Research and Therapy},
  year = {2021},
  doi = {10.29011/2574-710x.010116}
}
Kostenlos starten →